Valuation: PExA AB

Market Cap 27.06M 2.73M 2.43M 2.25M 2.05M 3.86M 260M 3.93M 10.61M 135M 10.26M 10.04M 435M P/E 2023
-2.18x
P/E 2024 -1.13x
Enterprise Value 21.47M 2.17M 1.93M 1.78M 1.63M 3.06M 206M 3.12M 8.42M 107M 8.14M 7.97M 345M EV / Sales 2023
3.92x
EV / Sales 2024 8.49x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+1.94%
1 month-3.08%
3 months-41.23%
6 months+25.00%
Current year+44.50%
1 month 0.3
Extreme 0.3
0.35
Current year 0.18
Extreme 0.182
0.83
1 year 0.14
Extreme 0.138
0.83
3 years 0.14
Extreme 0.138
0.83
5 years 0.14
Extreme 0.138
1.94
10 years 0.14
Extreme 0.138
9.5
Manager TitleAgeSince
Chief Executive Officer 55 -
Chief Tech/Sci/R&D Officer - 31/12/2017
Chief Tech/Sci/R&D Officer 65 31/12/2014
Director TitleAgeSince
Director/Board Member 66 31/12/2009
Chairman 72 30/01/2014
Director/Board Member 73 31/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%-.--%+93.25%-38.72% 3.92M
-0.93%+5.83%+30.71%+42.90% 258B
-1.06%+5.33%+11.13%+9.36% 163B
-0.27%+2.72%-2.05%+56.21% 151B
+0.57%+5.59%-54.57%-10.36% 63.97B
-1.70%+2.80%+18.74%+22.35% 50.78B
+1.47%+8.34%-12.03%-12.77% 50.94B
-1.47%+2.85%+23.86%+56.52% 49.49B
-0.85%+8.96%+8.00%+43.61% 50.68B
-1.62%+1.82%+31.45%+72.97% 43.64B
Average -0.35%+3.94%+14.85%+24.21% 88.09B
Weighted average by Cap. -0.63%+4.04%+10.46%+33.01%

Financials

2023 2024
Net sales 2.02M 204K 181K 168K 153K 288K 19.33M 293K 790K 10.07M 764K 748K 32.38M 720K 72.71K 64.61K 59.82K 54.49K 103K 6.9M 105K 282K 3.6M 273K 267K 11.56M
Net income -8.04M -813K -722K -669K -609K -1.15M -77.17M -1.17M -3.15M -40.19M -3.05M -2.98M -129M -10.16M -1.03M -912K -845K -770K -1.45M -97.5M -1.48M -3.99M -50.78M -3.85M -3.77M -163M
Net Debt -9.6M -970K -862K -798K -727K -1.37M -92.1M -1.4M -3.76M -47.96M -3.64M -3.56M -154M -5.59M -565K -502K -465K -424K -798K -53.66M -813K -2.19M -27.95M -2.12M -2.08M -89.87M
Projected Income Statement - Annual - PExA AB
Logo PExA AB
PExA AB is a Sweden-based company engaged in the advanced equipment and technology industry. The Company develops, manufactures and markets a non-invasive research instrument to study respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The instrument provides lung researchers with a non-invasive method for collecting microscopic particles, potential biomarkers for diseases, from small airways in exhaled air to diagnose, monitor and provide treatment of respiratory diseases.
Employees
3
  1. Stock Market
  2. Stocks
  3. PEXA B Stock